Microbiome drugs are delivered to specific locations within the gastrointestinal tract, so they must be formulated for targeted release without systemic absorption. With few examples on the market, formulation is a growing concern for developers of these medicines.
In this article from BioProcess International, the authors from Synthetic Biologics describe the rationale, design, and evaluation of microbiome products, while discussing challenges and possible solutions for localized intestinal delivery.